title: Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children.
abstract: OBJECTIVE
  To compare the safety and efficacy of ipratropium bromide 0.03% (IB) with beclomethasone dipropionate 0.042% (BDP) in the treatment of perennial rhinitis in children.
  
  
  METHODS
  Thirty-three children with nonallergic perennial rhinitis (NAPR) and 113 with allergic perennial rhinitis (APR) were randomly assigned to either IB or BDP for 6 months in a single-blind, multicenter protocol in which the physician was blinded to treatment. At each visit, patients and physicians rated symptom control of rhinorrhea, nasal congestion, and sneezing. Patients also completed quality of life questionnaires at baseline and after 6 months of therapy.
  
  
  RESULTS
  Both treatments showed a significant improvement in control of rhinorrhea, congestion, and sneezing compared with baseline over the 6 months of treatment (P < .05). Only for the control of sneezing was BDP consistently better than IB (P < .05). Among the patients given IB, 61% to 73% assessed the control of rhinorrhea as good or excellent on different study visit days, 43% to 60% similarly rated the control of nasal congestion, and 39% to 43% the control of sneezing. The results for BDP were 68% to 78% for the control of rhinorrhea, 55% to 72% for the control of nasal congestion, and 54% to 68% for the control of sneezing. Quality of life assessment documented that both drugs significantly reduced interference with daily activities and disturbance of mood due to rhinorrhea compared with baseline (P < .05). Both treatments were well tolerated with IB causing less nasal bleeding and irritation than BDP.
  
  
  CONCLUSIONS
  Ipratropium bromide was safe and effective in controlling rhinorrhea and diminishing the interference by rhinorrhea in school attendance, concentration on school work, and sleep. Ipratropium bromide was as effective as BDP in the control of rhinorrhea and showed a relatively good effect on congestion. Patient and physician assessment favored BDP in the control of sneezing.
authors.affiliation: National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver 80260, USA.
authors.forename: H
authors.initials: H
authors.lastname: Milgrom
authors.forename: R
authors.initials: R
authors.lastname: Biondi
authors.forename: J W
authors.initials: JW
authors.lastname: Georgitis
authors.forename: E O
authors.initials: EO
authors.lastname: Meltzer
authors.forename: Z M
authors.initials: ZM
authors.lastname: Munk
authors.forename: K
authors.initials: K
authors.lastname: Drda
authors.forename: C C
authors.initials: CC
authors.lastname: Wood
mesh_terms: D000293:Adolescent; D001507:Beclomethasone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D016037:Single-Blind Method; D011795:Surveys and Questionnaires
chemical_list: D010919:Placebos; D009241:Ipratropium; D001507:Beclomethasone